Lumexa Imaging (NASDAQ:LMRI) Upgraded at Raymond James Financial

Raymond James Financial upgraded shares of Lumexa Imaging (NASDAQ:LMRI) from an outperform rating to a strong-buy rating in a research report report published on Monday, Marketbeat.com reports. They currently have $23.00 target price on the stock.

Lumexa Imaging Price Performance

Shares of Lumexa Imaging stock opened at $13.79 on Monday. Lumexa Imaging has a fifty-two week low of $9.97 and a fifty-two week high of $19.45.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Assetmark Inc. acquired a new stake in shares of Lumexa Imaging in the fourth quarter worth approximately $36,000. TD Asset Management Inc acquired a new position in shares of Lumexa Imaging in the 4th quarter valued at $1,264,000. Geode Capital Management LLC purchased a new stake in shares of Lumexa Imaging during the 4th quarter valued at $1,548,000. Seven Grand Managers LLC purchased a new stake in shares of Lumexa Imaging during the 4th quarter valued at $11,942,000. Finally, JPMorgan Chase & Co. acquired a new stake in shares of Lumexa Imaging during the 4th quarter worth $15,954,000.

Lumexa Imaging Company Profile

We are one of the largest national providers of diagnostic imaging services(1). Our platform is integrated, scalable and has a proven track record of creating value for our stakeholders. As of September 30, 2025, we and our affiliates operated the second largest(1) outpatient imaging center footprint in the United States. It spans 184 centers(2)across 13 states and includes eight joint venture partnerships with health systems. Our centers are in attractive metropolitan statistical areas (“MSAs”).